Cargando…

Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma

BACKGROUND: Monoclonal antibodies (mAbs) targeting negative regulators, or checkpoint molecules (e.g. PD1/PD-L1 & CTLA4), of anti-tumoural T cells have demonstrated clinical efficacy in treating several neoplastic diseases. While many patients enjoy remarkable responses to checkpoint inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijayakumar, Gayathri, Palese, Peter, Goff, Peter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945240/ https://www.ncbi.nlm.nih.gov/pubmed/31676387 http://dx.doi.org/10.1016/j.ebiom.2019.10.032

Ejemplares similares

Microbubble and ultrasound radioenhancement of bladder cancer
por: Tran, W T, et al.
Publicado: (2012)

Prospects of nanoparticle-based radioenhancement for radiotherapy
por: Gerken, Lukas R. H., et al.
Publicado: (2023)

Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma
por: Numpadit, Supaporn, et al.
Publicado: (2023)

Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
por: Almasri, Firas, et al.
Publicado: (2023)

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
por: Wongariyapak, Amarin, et al.
Publicado: (2023)

STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
por: Shao, Xiaoyan, et al.
Publicado: (2019)

Cellular fate and performance of group IV metal organic framework radioenhancers
por: Neuer, Anna Lena, et al.
Publicado: (2022)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
por: Xie, Daoyuan, et al.
Publicado: (2023)

Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
por: LaRocca, Christopher J., et al.
Publicado: (2018)

Oncolytic viruses in melanoma
por: Robinson, Camille, et al.
Publicado: (2022)

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
por: Fournier, Philippe, et al.
Publicado: (2013)

Therapeutic potential of oncolytic Newcastle disease virus: a critical review
por: Tayeb, Shay, et al.
Publicado: (2015)

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus
por: Pathak, Upasana, et al.
Publicado: (2023)

Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma
por: de Graaf, J. Fréderique, et al.
Publicado: (2022)

Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses
por: Liu, Tianyan, et al.
Publicado: (2020)

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020)

Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
por: Lovatt, Charlotte, et al.
Publicado: (2023)

Adaptation of the Newcastle Disease Virus to Cell Cultures for Enhancing Its Oncolytic Properties
por: Yurchenko, K. S., et al.
Publicado: (2019)

Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
por: Huang, Fang, et al.
Publicado: (2022)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

Anti-Tumor Effects of an Oncolytic Adenovirus Expressing Hemagglutinin-Neuraminidase of Newcastle Disease Virus in Vitro and in Vivo
por: He, Dongyun, et al.
Publicado: (2014)

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
por: Huang, Feng-Ying, et al.
Publicado: (2020)

Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma
por: Baiocchi, Leonardo, et al.
Publicado: (2022)

Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
por: Friedman, Avner, et al.
Publicado: (2018)

Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
por: Buijs, Pascal, et al.
Publicado: (2015)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
por: Schirrmacher, Volker, et al.
Publicado: (2019)

Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis
por: Keshavarz, Mohsen, et al.
Publicado: (2020)

Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
por: Schirrmacher, Volker
Publicado: (2022)

Papaverine Enhances the Oncolytic Effects of Newcastle Disease Virus on Breast Cancer In Vitro and In Vivo
por: Akram, Sura, et al.
Publicado: (2023)

The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro
por: Tsakanova, Gohar, et al.
Publicado: (2021)

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2020)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Dosimetry and Radioenhancement Comparison of Gold Nanoparticles in Kilovoltage and Megavoltage Radiotherapy using MAGAT Polymer Gel Dosimeter
por: Farahani, S., et al.
Publicado: (2019)

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience
por: Bagley, Alexander F., et al.
Publicado: (2022)

Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
por: Chai, Zheng, et al.
Publicado: (2014)

Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
por: Jiang, Ke, et al.
Publicado: (2018)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice
por: Wei, Ding, et al.
Publicado: (2015)

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
por: Kuryk, Lukasz, et al.
Publicado: (2019)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o2o9cp75to7d4pf9ljhn8vm42g